Competent Cells Market Highlights
The global competent cells market share report has evaluated the industry at USD 1.9 Billion in 2022 and is expected to expand from USD 2.1 Billion in 2023 to USD 4.8 Billion by 2032, at a compound annual growth rate (CAGR) of 10.90% between 2023 and 2032.
Competent cells refer to bacterial cells that have been either genetically modified or treated in such a way as to permit them to absorb external DNA, including plasmids or genomic DNA. These cells are commonly utilized in molecular biology methodologies such as DNA cloning, where foreign DNA is inserted into a vector and subsequently injected into competent cells. Following this, the cells are grown in a culture, thereby enabling researchers to investigate the function of the foreign DNA, manufacture large quantities of DNA for downstream applications, or generate genetically modified organisms.
The usage of molecular biology methods in research and industrial environments has grown in recent years, resulting in a significant expansion of the market for competent cells. These cells are indispensable instruments in such techniques, providing scientists with the capability to introduce external DNA into bacterial cells for research purposes or to create genetically modified organisms.
The global Competent Cells market has been segmented based type, application, and end-user.
On the basis of application, the market is segmented into cloning, protein expression, and other. The cloning segment was attributed to holding the largest market share in 2022.
Based on type, the global Competent Cells market has been segmented into chemically competent cells and electrocompetent cells. The chemically competent cells segment was expected to hold the largest market share in 2022.
Based on End User, the global Competent Cells market has been segmented into pharmaceutical and biotechnology companies, academic research institutes, and others. The academic research institutes segment was expected to hold the largest market share in 2022.
The global Competent Cells market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Competent Cells market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Competent Cells market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Competent Cells market comprises of Middle East, Africa, and Latin America.
The largest market share for Competent Cells was maintained by the North American regional sector. The development is attributable to in-depth study on DNA cloning technologies, expanding biotechnology research, significant regional RD spending, and the presence of big market rivals. For instance, according to an article from the NIH dated March 2022, funding for biotechnology research in the United States was $7,847 million in 2021 and is predicted to climb to $8,104 million by 2030.
Moreover, Europe is expected to experience steady growth in the global competent cells market as a result of rising commercial demand for recombinant products and significant research activities in recombinant therapies due to local technical advancement.
Additionally, a significant percentage of the global market for competent cells would come from the Asia-Pacific region. Large market companies' presence and in-depth research into DNA cloning methods are credited with the expansion. For instance, Takara Bio Inc. declared in January 2021 that the Center for Gene and Cell Processing II, its new production and research facility, had been finished in Shiga, Japan.
Furthermore, the rest of the world's Competent Cells market is divided into the Middle East, Africa, and Latin America. The competent cells market in the LATEM and MEA regions is expected to experience significant growth in the coming years due to the increasing prevalence of genetic disorders, rising research activities, and increasing government funding for research and development.
MRFR recognizes the following companies as the top key players in its competent cells market trends report —Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Inc., Takara Bio Inc., New England Biolabs (UK) Ltd., HiMedia Laboratories, Zymo Research, Avantor, TransGen Biotech Co., Ltd, Scarab Genomics, Lucigen Corporation, Genscript Corporation, Tonbo Biosciences, Enzynomics co Ltd, Klee GmbH, and NZYTech, Lda.
Key Findings of the Study
- The global Competent Cells market is expected to reach USD 4.8 billion by 2032, at a CAGR of 10.90% during the forecast period.
- The Asia Pacific region accounted for the fastest-growing global market due to the development is attributable to in-depth study on DNA cloning technologies, expanding biotechnology research, significant regional RD spending, and the presence of big market rivals
- Based on type, the chemically competent cells segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.
- Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Inc., Takara Bio Inc., New England Biolabs (UK) Ltd., HiMedia Laboratories, Zymo Research, Avantor, TransGen Biotech Co., Ltd, Scarab Genomics, Lucigen Corporation, Genscript Corporation, Tonbo Biosciences, Enzynomics co Ltd, Klee GmbH, and NZYTech, Lda.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)